The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial
Open accessAbstract
CDK4/6 inhibition with endocrine therapy is now a standard of care for advanced estrogen receptor–positive breast cancer. Mechanisms of CDK4/6 inhibitor resistance have been described preclinically, with limited evidence from clinical samples. We conducted paired baseline and end-of-treatment circulating tumor DNA sequencing from 195 patients in the PALOMA-3 randomized phase III trial of palbociclib plus fulvestrant versus placebo plus fulvestrant. We show that clonal evolution occurs frequently during treatment, reflecting substantial subclonal complexity in breast cancer that has progressed after prior endocrine therapy. RB1 mutations emerged only in the palbociclib plus fulvestrant arm and in a minority of patients (6/127, 4.7%, P = 0.041). New driver mutations emerged in PIK3CA (P = 0.00069) and ESR1 after treatment in both arms, in particular ESR1 Y537S (P = 0.0037). Evolution of driver gene mutations was uncommon in patients progressing early on palbociclib plus fulvestrant but common in patients progressing later on treatment. These findings inform future treatment strategies to address resistance to palbociclib plus fulvestrant. Significance: Acquired mutations from fulvestrant are a major driver of resistance to fulvestrant and palbociclib combination therapy. ESR1 Y537S mutation promotes resistance to fulvestrant. Clonal evolution results in frequent acquisition of driver mutations in patients progressing late on therapy, which suggests that early and late progression have distinct mechanisms of resistance. Cancer Discov; 8(11); 1390–403. ©2018 AACR. See related commentary by Schiff and Jeselsohn, p. 1352. This article is highlighted in the In This Issue feature, p. 1333
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Van der Auwera, G. A., Carneiro, M. O., Hartl, C., Poplin, R., del Angel, G., Levy‐Moonshine, A., Jordan, T., Shakir, K., Roazen, D., Thibault, J., et al. (2013) · Current Protocols in Bioinformatics · doi:10.1002/0471250953.bi1110s43 · Cited by 6,687
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
Mermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. L., Beroukhim, R., & Getz, G. (2011) · Genome Biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,550
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007 · cited 1×
“Multiple phase III studies have now demonstrated that CDK4/6 inhibitors significantly prolong progression free survival in combination with endocrine therapy in ER positive breast cancer (5-8), identifying the CDK4/6-Rb axis as central to the biology of this subtype of breast cancer.”
CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing
Talevich, E., Shain, A. H., Botton, T., & Bastian, B. C. (2016) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004873 · Cited by 2,094
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039 · cited 1×
“Multiple phase III studies have now demonstrated that CDK4/6 inhibitors significantly prolong progression free survival in combination with endocrine therapy in ER positive breast cancer (5-8), identifying the CDK4/6-Rb axis as central to the biology of this subtype of breast cancer.”
Self-citationCristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Self-citationMONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S.-C., Manso, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.6155 · Cited by 1,744
Pereira, B., Chin, S.-F., Rueda, O. M., Vollan, H.-K. M., Provenzano, E., Bardwell, H. A., Pugh, M., Jones, L., Russell, R., Sammut, S.-J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11479 · Cited by 1,717
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680 · cited 2×
“Multiple phase III studies have now demonstrated that CDK4/6 inhibitors significantly prolong progression free survival in combination with endocrine therapy in ER positive breast cancer (5-8), identifying the CDK4/6-Rb axis as central to the biology of this subtype of breast cancer.”
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Allele-specific copy number analysis of tumors
Van Loo, P., Nordgard, S. H., Lingjærde, O. C., Russnes, H. G., Rye, I. H., Sun, W., Weigman, V. J., Marynen, P., Zetterberg, A., Naume, B., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009843107 · Cited by 1,226
Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B. S., & Swanton, C. (2016) · Genome Biology · doi:10.1186/s13059-016-0893-4 · Cited by 1,216
Integrated digital error suppression for improved detection of circulating tumor DNA
Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D. M., Chabon, J. J., Scherer, F., Stehr, H., Liu, C. L., Bratman, S. V., Say, C., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3520 · Cited by 1,099
Harbour, J. W., Luo, R. X., Santi, A. D., Postigo, A. A., & Dean, D. C. (1999) · Cell · doi:10.1016/s0092-8674(00)81519-6 · Cited by 1,057
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
Adalsteinsson, V. A., Ha, G., Freeman, S. S., Choudhury, A. D., Stover, D. G., Parsons, H. A., Gydush, G., Reed, S. C., Rotem, D., Rhoades, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00965-y · Cited by 1,051
PyClone: statistical inference of clonal population structure in cancer
Roth, A., Khattra, J., Yap, D., Wan, A., Laks, E., Biele, J., Ha, G., Aparicio, S., Bouchard-Côté, A., & Shah, S. P. (2014) · Nature Methods · doi:10.1038/nmeth.2883 · Cited by 999
VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research
Lai, Z., Markovets, A., Ahdesmaki, M., Chapman, B., Hofmann, O., McEwen, R., Johnson, J., Dougherty, B., Barrett, J. C., & Dry, J. R. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw227 · Cited by 970
Pan-cancer analysis of the extent and consequences of intratumor heterogeneity
Andor, N., Graham, T. A., Jansen, M., Xia, L. C., Aktipis, C. A., Petritsch, C., Ji, H. P., & Maley, C. C. (2016) · Nature Medicine · doi:10.1038/nm.3984 · Cited by 768
Herrera-Abreu, M. T., Palafox, M., Asghar, U., Rivas, M. A., Cutts, R. J., Garcia-Murillas, I., Pearson, A., Guzman, M., Rodriguez, O., Grueso, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0728 · Cited by 762
Self-citationPlasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
Fribbens, C., O’Leary, B., Kilburn, L., Hrebien, S., Garcia-Murillas, I., Beaney, M., Cristofanilli, M., Andre, F., Loi, S., Loibl, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3061 · Cited by 722 · cited 13×
“The PALOMA-3 study was the first phase III trial of a CDK4/6 inhibitor in ER+, HER2− advanced breast cancer, randomizing both premenopausal and postmenopausal patients who had previously progressed on endocrine therapy to either palbociclib plus fulvestrant or placebo plus fulvestrant, and demonstrating an improvement…”
InfluentialSelf-citationThe retinoblastoma gene product regulates progression through the G1 phase of the cell cycle
Goodrich, D. W., Wang, N. P., Qian, Y.-W., Lee, E. Y.-H. P., & Lee, W.-H. (1991) · Cell · doi:10.1016/0092-8674(91)90181-w · Cited by 707
ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
Jeselsohn, R., Buchwalter, G., De Angelis, C., Brown, M., & Schiff, R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.117 · Cited by 704
Chandarlapaty, S., Chen, D., He, W., Sung, P., Samoila, A., You, D., Bhatt, T., Patel, P., Voi, M., Gnant, M., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1279 · Cited by 494
Plasma AR and abiraterone-resistant prostate cancer
Romanel, A., Tandefelt, D. G., Conteduca, V., Jayaram, A., Casiraghi, N., Wetterskog, D., Salvi, S., Amadori, D., Zafeiriou, Z., Rescigno, P., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac9511 · Cited by 441
Yang, C., Li, Z., Bhatt, T., Dickler, M., Giri, D., Scaltriti, M., Baselga, J., Rosen, N., & Chandarlapaty, S. (2017) · Oncogene · doi:10.1038/onc.2016.379 · Cited by 415
Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis
Lefebvre, C., Bachelot, T., Filleron, T., Pedrero, M., Campone, M., Soria, J.-C., Massard, C., Lévy, C., Arnedos, M., Lacroix-Triki, M., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002201 · Cited by 394
Self-citationCondorelli, R., Spring, L., O’Shaughnessy, J., Lacroix, L., Bailleux, C., Scott, V., Dubois, J., Nagy, R. J., Lanman, R. B., Iafrate, A. J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx784 · Cited by 394
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists
Toy, W., Weir, H., Razavi, P., Lawson, M., Goeppert, A. U., Mazzola, A. M., Smith, A., Wilson, J., Morrow, C., Wong, W. L., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1523 · Cited by 368
Tumor clone dynamics in lethal prostate cancer
Carreira, S., Romanel, A., Goodall, J., Grist, E., Ferraldeschi, R., Miranda, S., Prandi, D., Lorente, D., Frenel, J.-S., Pezaro, C., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009448 · Cited by 340
Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
Turner, N. C., Neven, P., Loibl, S., & Andre, F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32419-9 · Cited by 205
Self-citationClonEvol: clonal ordering and visualization in cancer sequencing
Dang, H. X., White, B. S., Foltz, S. M., Miller, C. A., Luo, J., Fields, R. C., & Maher, C. A. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx517 · Cited by 179
Mutational Signatures in Breast Cancer: The Problem at the DNA Level
Nik‐Zainal, S., & Morganella, S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2810 · Cited by 147
Boeva, V., Popova, T. V., Liénard, M., Toffoli, S., Kamal, M. T., Tourneau, C. L., Gentien, D., Servant, N., Gestraud, P., Frio, T. R., et al. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu436 · Cited by 141
Savas, P. S., Teo, Z. L., Lefèvre, C. M., Flensburg, C., Caramia, F., Alsop, K., Mansour, M., Francis, P. A., Thorne, H., Silva, M. J., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002204 · Cited by 137
Self-citationUnraveling the clonal hierarchy of somatic genomic aberrations
Prandi, D., Baca, S. C., Romanel, A., Barbieri, C. E., Mosquera, J., Fontugne, J., Beltran, H., Sboner, A., Garraway, L. A., Rubin, M. A., et al. (2014) · Genome biology · doi:10.1186/s13059-014-0439-6 · Cited by 104
Mayer, I. A., & Arteaga, C. L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.9591 · Cited by 38
Turner, N. C., André, F., Cristofanilli, M., Verma, S., Iwata, H., Loi, S., Harbeck, N., Ro, J., Colleoni, M. A., Zhang, K., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.sabcs16-p4-22-06 · Cited by 11
Self-citation
Cited by
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622
Self-citationOverall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276
“Capecitabine 66 (27) 43 (24) 36 (27) 36 (26) 20 (18) 24 (28)”
Self-citationLiquid biopsy enters the clinic — implementation issues and future challenges
Ignatiadis, M., Sledge, G. W., & Jeffrey, S. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00457-x · Cited by 1,191
Liquid biopsy and minimal residual disease - latest advances and implications for cure
Pantel, K., & Alix-Panabières, C. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0187-3 · Cited by 1,110
Liquid Biopsy: From Discovery to Clinical Application
Alix-Panabières, C., & Pantel, K. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1311 · Cited by 953
Metadata
- Authors
- O'Leary, B., Cutts, R. J., Liu, Y., Hrebien, S., Huang, X., Fenwick, K., André, F., Loibl, S., Loi, S., Garcia-Murillas, I., Cristofanilli, M., Huang Bartlett, C., & Turner, N. C.
- Venue
- Cancer Discovery
- Published
- 2018-11-01
- Volume
- 8
- Issue
- 11
- Pages
- 1390-1403
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2892043300
- Cited by
- 650
- References
- 44
- FWCI
- 37.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.